Joaquim Bellmunt European Urology Supplements

Slides:

Advertisements

Similar presentations

Volume 60, Issue 4, Pages (October 2011)

Advertisements

Pascal Rischmann European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum John M. Fitzpatrick, Marc.

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Management of Acute and Chronic Retention in Men

Olivier Traxer European Urology Supplements

Shock Wave Lithotripsy for Renal and Ureteric Stones

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Bladder Cancer: Management and Future Directions

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Shock Wave Lithotripsy for Renal and Ureteric Stones

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

What is New in Bladder Cancer Diagnosis and Management?

Back to the Future: Introduction and Conclusions

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Volume 66, Issue 5, Pages (November 2014)

A Novel Treatment of Premature Ejaculation

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy Kerstin Junker, Sebastian Hölters,

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Volume 26, Issue 2, Pages (February 2018)

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Kidney Cancer: Highlights from 2006

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

Pharmacotherapy in Stress and Mixed Incontinence

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Ureteropelvic Junction Obstruction

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Radiofrequency Ablation of Metastases from Renal Cell Carcinoma: Technique, Complications, and Midterm Outcome Christian Kloeters, Ann-Kathrin Mager,

The Impact of Premature Ejaculation on Partners and Relationships

Diagnosis and Management of Cryptorchidism

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Pathology and Molecular Pathogenesis of Renal Cell Carcinoma

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Presentation transcript:

The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma Joaquim Bellmunt European Urology Supplements Volume 7, Issue 2, Pages 55-62 (February 2008) DOI: 10.1016/j.eursup.2007.12.004 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Computed tomography scan of lung nodule (A) before and (B) 9 wk after initiation of treatment. European Urology Supplements 2008 7, 55-62DOI: (10.1016/j.eursup.2007.12.004) Copyright © 2007 European Association of Urology Terms and Conditions